{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T01:47:32Z","timestamp":1791856052846,"version":"4.3.4"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Center for Drug Reevaluation, NMPA","award":["CDRZ20234001-2"],"award-info":[{"award-number":["CDRZ20234001-2"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s40121-026-01439-9","type":"journal-article","created":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T15:46:45Z","timestamp":1789141605000},"page":"3085-3100","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Preliminary Safety Assessment of a Quadrivalent Subunit Influenza Vaccine in China: A Phase IV Study"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-2041-8508","authenticated-orcid":false,"given":"Liuyang","family":"Kang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingwei","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Zang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youcai","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyu","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongxing","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,11]]},"reference":[{"issue":"12","key":"1439_CR1","first-page":"2097","volume":"46","author":"National Immunization Advisory Committee (NIAC) Technical Working Group (TWG), Influenza Vaccination TWG","year":"2025","unstructured":"National Immunization Advisory Committee (NIAC) Technical Working Group (TWG), Influenza Vaccination TWG. Technical guidelines for seasonal influenza vaccination in China (2025\u20132026). Chin J Epidemiol. 2025;46(12):2097\u2013107.","journal-title":"Chin J Epidemiol"},{"issue":"1","key":"1439_CR2","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2025.2497576","volume":"21","author":"J Wang","year":"2025","unstructured":"Wang J, Xiong Y, Li B, et al. A 14-year influenza reinfection surveillance in Chongqing, China: a retrospective analysis. Hum Vaccin Immunother. 2025;21(1):2497576.","journal-title":"Hum Vaccin Immunother"},{"key":"1439_CR3","unstructured":"Hu Y, Gong J. A meta-analysis of influenza attack rate in unvaccinated population, 2024; 51(6): 386-393"},{"issue":"6","key":"1439_CR4","doi-asserted-by":"publisher","first-page":"S81","DOI":"10.1016\/j.jval.2024.03.429","volume":"27","author":"C Chen","year":"2011","unstructured":"Chen C, Peng N, Tan J. EE130 economic burden of seasonal influenza in mainland China from 2011 to 2019. Value Health. 2011;27(6):S81.","journal-title":"Value Health"},{"issue":"10","key":"1439_CR5","first-page":"1507","volume":"44","author":"National Immunization Advisory Committee (NIAC) Technical Working Group (TWG), Influenza Vaccination TWG","year":"2023","unstructured":"National Immunization Advisory Committee (NIAC) Technical Working Group (TWG), Influenza Vaccination TWG. Technical guidelines for seasonal influenza vaccination in China (2023\u20132024). Chin J Epidemiol. 2023;44(10):1507\u201330.","journal-title":"Chin J Epidemiol"},{"key":"1439_CR6","unstructured":"Yang XM, Gao F, Yu YX. Contemporary New Vaccines (2nd Edition) [M]. Beijing: Higher Education Press."},{"issue":"29","key":"1439_CR7","doi-asserted-by":"publisher","first-page":"3871","DOI":"10.1016\/j.vaccine.2021.05.070","volume":"39","author":"Y Wang","year":"2021","unstructured":"Wang Y, Zhang Y, Wu H, et al. Safety and immunogenicity of a quadrivalent inactivated subunit non-adjuvanted influenza vaccine: a randomized, double-blind, active-controlled phase 1 clinical trial. Vaccine. 2021;39(29):3871\u20138.","journal-title":"Vaccine"},{"issue":"34","key":"1439_CR8","doi-asserted-by":"publisher","first-page":"4933","DOI":"10.1016\/j.vaccine.2022.06.078","volume":"40","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Wang Y, Jia C, et al. Immunogenicity and safety of an egg culture-based quadrivalent inactivated non-adjuvanted subunit influenza vaccine in subjects \u22653 years: a randomized, multicenter, double-blind, active-controlled phase III, non-inferiority trial. Vaccine. 2022;40(34):4933\u201341.","journal-title":"Vaccine"},{"issue":"5","key":"1439_CR9","doi-asserted-by":"publisher","first-page":"467","DOI":"10.3390\/vaccines13050467","volume":"13","author":"L Huang","year":"2025","unstructured":"Huang L, Li G, Zhang Y, et al. The safety and immunogenicity of a quadrivalent influenza subunit vaccine in healthy children aged 6\u201335 months: a randomized, blinded and positive-controlled Phase III clinical trial. Vaccines. 2025;13(5):467.","journal-title":"Vaccines"},{"issue":"5","key":"1439_CR10","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.biologicals.2012.07.007","volume":"40","author":"J Bonhoeffer","year":"2012","unstructured":"Bonhoeffer J, Black S, Izurieta H, et al. Current status and future directions of post-marketing vaccine safety monitoring with focus on USA and Europe. Biologicals. 2012;40(5):393\u20137.","journal-title":"Biologicals"},{"issue":"08","key":"1439_CR11","first-page":"464","volume":"14","author":"T Cai","year":"2017","unstructured":"Cai T, Yang Y, Wang YL, et al. Analysis of active surveillance models for post-marketing vaccine safety. Chin J Pharmacovigilance. 2017;14(08):464\u20139.","journal-title":"Chin J Pharmacovigilance"},{"issue":"02","key":"1439_CR12","first-page":"351","volume":"42","author":"YX Sun","year":"2021","unstructured":"Sun YX, Liu ZK, Nie XL, et al. Near real-time active surveillance for post-marketing vaccine safety. Chin J Epidemiol. 2021;42(02):351\u20136.","journal-title":"Chin J Epidemiol"},{"issue":"2","key":"1439_CR13","doi-asserted-by":"publisher","first-page":"26","DOI":"10.46234\/ccdcw2019.009","volume":"1","author":"S Black","year":"2019","unstructured":"Black S, Global Vaccine Data Network, Usa, Cincinnati Children\u2019s Hospital, Usa. The importance of active surveillance in the assessment of vaccine safety. China CDC Wkly. 2019;1(2):26\u20137.","journal-title":"China CDC Wkly"},{"issue":"6","key":"1439_CR14","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1177\/014107689108400612","volume":"84","author":"AP Fletcher","year":"1991","unstructured":"Fletcher AP. Spontaneous adverse drug reaction reporting vs event monitoring: a comparison. J R Soc Med. 1991;84(6):341\u20134.","journal-title":"J R Soc Med"},{"issue":"12","key":"1439_CR15","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.2105\/AJPH.85.12.1706","volume":"85","author":"S Rosenthal","year":"1995","unstructured":"Rosenthal S, Chen R, Rosenthal S. The reporting sensitivities of two passive surveillance systems for vaccine adverse events. Am J Public Health. 1995;85(12):1706\u20139.","journal-title":"Am J Public Health"},{"issue":"1","key":"1439_CR16","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1208\/s12248-007-9004-5","volume":"10","author":"J Weaver","year":"2008","unstructured":"Weaver J, Willy M, Avigan M. Informatic tools and approaches in postmarketing pharmacovigilance used by FDA. AAPS J. 2008;10(1):35\u201341.","journal-title":"AAPS J"},{"issue":"3","key":"1439_CR17","first-page":"279","volume":"33","author":"XJ Pan","year":"2026","unstructured":"Pan XJ, Zhou Y, Liang H, et al. Reflections on the construction of safety monitoring indicators in the evaluation of vaccine regulatory systems at CDC institutions. Pract Prevent Med. 2026;33(3):279\u201384.","journal-title":"Pract Prevent Med"},{"issue":"2","key":"1439_CR18","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1586\/14760584.2014.866895","volume":"13","author":"NW Crawford","year":"2014","unstructured":"Crawford NW, Clothier H, Hodgson K, et al. Active surveillance for adverse events following immunization. Expert Rev Vacc. 2014;13(2):265\u201376.","journal-title":"Expert Rev Vacc"},{"issue":"5","key":"1439_CR19","first-page":"261","volume":"4","author":"D Dong","year":"2007","unstructured":"Dong D, Tian CH, Sun LH. Current status and reflections on the adverse event surveillance system for vaccines in China [J]. Chin J Pharmacovigilance. 2007;4(5):261\u20134.","journal-title":"Chin J Pharmacovigilance"},{"key":"1439_CR20","volume-title":"Sample size tables for clinical studies","author":"D Machin","year":"1997","unstructured":"Machin D, Campbell MJ, Fayers P, et al. Sample size tables for clinical studies. Blackwell Science; 1997."},{"key":"1439_CR21","unstructured":"China Food and Drug Administration. Notice of the China Food and Drug Administration on issuing the Guiding Principles for Quality Management of Vaccine Clinical Trials (Trial Version): CFDA Announcement No. 228 of 2013 [EB\/OL]. (2014\u201302\u201310) [2026\u201307\u201310]. https:\/\/www.gov.cn\/gongbao\/content\/2014\/content_2580994.htm."},{"issue":"40","key":"1439_CR22","doi-asserted-by":"publisher","first-page":"6030","DOI":"10.1016\/j.vaccine.2018.04.043","volume":"36","author":"S van de Witte","year":"2018","unstructured":"van de Witte S, Nauta J, Montomoli E, et al. A phase III randomised trial of the immunogenicity and safety of quadrivalent versus trivalent inactivated subunit influenza vaccine in adult and elderly subjects, assessing both anti-haemagglutinin and virus neutralisation antibody responses. Vaccine. 2018;36(40):6030\u20138.","journal-title":"Vaccine"},{"issue":"1","key":"1439_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/21645515.2021.1885278","volume":"18","author":"I Basu","year":"2022","unstructured":"Basu I, Agarwal M, Shah V, et al. Immunogenicity and safety of two quadrivalent influenza vaccines in healthy adult and elderly participants in India - a phase III, active-controlled, randomized clinical study. Hum Vaccin Immunother. 2022;18(1):1\u201310.","journal-title":"Hum Vaccin Immunother"},{"issue":"16","key":"1439_CR24","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1056\/NEJMoa2024848","volume":"385","author":"T Nolan","year":"2021","unstructured":"Nolan T, Fortanier AC, Leav B, et al. Efficacy of a cell-culture-derived quadrivalent influenza vaccine in children. N Engl J Med. 2021;385(16):1485\u201395.","journal-title":"N Engl J Med"},{"issue":"5","key":"1439_CR25","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2022-057509","volume":"150","author":"BJ Essink","year":"2022","unstructured":"Essink BJ, Heeringa M, Jeanfreau RJ, et al. Safety and immunogenicity of cell-based quadrivalent influenza vaccine: a randomized trial. Pediatrics. 2022;150(5):e2022057509.","journal-title":"Pediatrics"},{"key":"1439_CR26","unstructured":"Center for Drug Evaluation, National Medical Products Administration. Notice on the second public consultation for the Technical Guideline for Clinical Trials of Influenza Virus Vaccines (Draft for Comment) [EB\/OL]. (2025\u201311\u201310) [2026\u201307\u201310]. https:\/\/www.cde.org.cn\/main\/news\/viewInfoCommon\/3c83886fde908b6119f925e216e71693."},{"issue":"29","key":"1439_CR27","doi-asserted-by":"publisher","first-page":"3360","DOI":"10.1016\/j.vaccine.2015.05.008","volume":"33","author":"LM Christian","year":"2015","unstructured":"Christian LM, Porter K, Karlsson E, et al. Proinflammatory cytokine responses correspond with subjective side effects after influenza virus vaccination. Vaccine. 2015;33(29):3360\u20136.","journal-title":"Vaccine"},{"key":"1439_CR28","first-page":"7","volume":"2016","author":"A Bahadoran","year":"1841","unstructured":"Bahadoran A, Lee SH, Wang SM, et al. Immune responses to influenza virus and its correlation to age and inherited factors. Front Microbiol. 1841;2016:7.","journal-title":"Front Microbiol"},{"issue":"1821","key":"1439_CR29","doi-asserted-by":"publisher","first-page":"20143085","DOI":"10.1098\/rspb.2014.3085","volume":"282","author":"AK Simon","year":"1821","unstructured":"Simon AK, Hollander GA, McMichael A. Evolution of the immune system in humans from infancy to old age. Proc R Soc B Biol Sci. 1821;282(1821):20143085.","journal-title":"Proc R Soc B Biol Sci"},{"key":"1439_CR30","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s12979-019-0164-9","volume":"16","author":"SN Crooke","year":"2019","unstructured":"Crooke SN, Ovsyannikova IG, Poland GA, et al. Immunosenescence and human vaccine immune responses. Immunity & Ageing\u202f: I & A. 2019;16:25.","journal-title":"Immunity & Ageing : I & A"},{"issue":"1","key":"1439_CR31","doi-asserted-by":"publisher","DOI":"10.1186\/s40794-024-00228-x","volume":"10","author":"Z Kou","year":"2024","unstructured":"Kou Z, Li X, Liu T, et al. A post-marketing study to evaluate the safety and immunogenicity of a quadrivalent influenza split-virion vaccine in elderly people aged 60 years and older. Trop Dis Travel Med Vaccin. 2024;10(1):18.","journal-title":"Trop Dis Travel Med Vaccin"},{"issue":"4","key":"1439_CR32","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s40264-024-01395-8","volume":"47","author":"G Dos Santos","year":"2014","unstructured":"Dos Santos G, Devadiga R, Kim CS, et al. An 8-year prospective, observational, multi-centre post-marketing safety surveillance study conducted in South Korea (2014\u20132022) following the introduction of GSK\u2019s inactivated quadrivalent seasonal influenza vaccine (Fluarix Tetra) for subjects aged 6 months and older. Drug Saf. 2014;47(4):365\u201375.","journal-title":"Drug Saf"},{"issue":"21","key":"1439_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2024.126182","volume":"42","author":"Y Gao","year":"2024","unstructured":"Gao Y, Yang X, Li X, et al. Lot-to-lot consistency, immunogenicity and safety of a quadrivalent split virion inactivated influenza vaccine in healthy population aged 9\u201359 years: a randomized, double-blind, controlled, phase IV clinical trial. Vaccine. 2024;42(21):126182.","journal-title":"Vaccine"},{"issue":"1","key":"1439_CR34","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2025.2578084","volume":"21","author":"V Jain","year":"2023","unstructured":"Jain V, Cauwberghs F, Qian H, et al. Reactogenicity, safety, and immunogenicity of a quadrivalent seasonal influenza vaccine in adults aged 65 years and older: phase 4 study results from India during December 2023\u2013February 2024. Hum Vaccin Immunother. 2023;21(1):2578084.","journal-title":"Hum Vaccin Immunother"},{"issue":"2","key":"1439_CR35","first-page":"41","volume":"50","author":"JH Xia","year":"2022","unstructured":"Xia JH, Zhao SJ, Wang P, et al. Post-marketing safety evaluation of quadrivalent split-virion influenza vaccine in four regions. Progress Microbiol and Immunol. 2022;50(2):41\u20136.","journal-title":"Progress Microbiol and Immunol"},{"issue":"1","key":"1439_CR36","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1093\/trstmh\/tru167","volume":"109","author":"SL Klein","year":"2015","unstructured":"Klein SL, Marriott I, Fish EN. Sex-based differences in immune function and responses to vaccination. Trans R Soc Trop Med Hyg. 2015;109(1):9\u201315.","journal-title":"Trans R Soc Trop Med Hyg"},{"issue":"4","key":"1439_CR37","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1007\/s11096-023-01591-z","volume":"45","author":"L Shafei","year":"2023","unstructured":"Shafei L, Mekki L, Maklad E, et al. Factors that influence patient and public adverse drug reaction reporting: a systematic review using the theoretical domains framework. Int J Clin Pharm. 2023;45(4):801\u201313.","journal-title":"Int J Clin Pharm"},{"key":"1439_CR38","doi-asserted-by":"crossref","unstructured":"Wei M, Pan Y, Wang K, et al. Post-marketing active surveillance of adverse events following quadrivalent subunit influenza vaccine in healthy participants aged \u2265 3 years in China. Infect Dis and Therapy, 2026; 1\u201316.","DOI":"10.1007\/s40121-026-01354-z"}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-026-01439-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40121-026-01439-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-026-01439-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T01:02:18Z","timestamp":1791853338000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40121-026-01439-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,11]]},"references-count":38,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["1439"],"URL":"https:\/\/doi.org\/10.1007\/s40121-026-01439-9","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"value":"2193-8229","type":"print"},{"value":"2193-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,11]]},"assertion":[{"value":"20 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors have declared no conflicts of interest. Mingwei Wei, Hui Jiang, Xia Zang, Yu Pan, Hongxing Pan, and Hui Jin have nothing to disclose. Youcai An, Jing Yang, Siyu Tian, Liuyang Kang, and Hang Tao are employees of Ab&B Biotech Co., Ltd.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study adheres to the ethical principles for medical research involving human participants as outlined in the Declaration of Helsinki. This study was reviewed and approved by the Ethics Committee of Jiangsu Provincial Center for Disease Control and Prevention (approval number JSJK2023-B016-02). The study was registered in the Drug Clinical Trial Registration and Information Disclosure Platform of China (\n                      \n                      ) with registration number CTR20244333, and in ClinicalTrials.gov with registration number NCT07710586.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}